- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Education
- Most viewed
- View all
ASCO 2009, Cytotoxics, Haematology oncology, North America
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute
Bortezomib based therapies for myeloma
Dr Paul Richardson, Hematologic Oncology Dept, Dana-Farber Cancer Institute, speaking at ASCO 2009 about Bortezomib based therapies in relapsed and refractory myeloma. Tanespimycin with bortezomib (some neuroprotection found). HSP-90 inhibtion is an important therapeutic target. Also covers his highlights from the conference. Also lenalidomide with bortezomib and dexamethasone (RVD platform)
Specialities
- Policy (10)
- Biology (62)
- Bone (24)
- Brain and nervous system (14)
- Breast (190)
- Colorectal and gastrointestinal (43)
- Community (83)
- Diagnostics (37)
- Drug development (85)
- Epidemiology and prevention (53)
- Haematology oncology (60)
- Head and neck (17)
- Hepatobiliary pancreatic (17)
- Lung and pleura (47)
- Melanoma and skin (27)
- Ovary and gynaecology (33)
- Paediatric (17)
- Prostate and urology (42)
- Psycho social (19)
- Radiotherapy (27)
- Sarcomas (15)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment